0000950170-24-032406.txt : 20240315
0000950170-24-032406.hdr.sgml : 20240315
20240315191406
ACCESSION NUMBER: 0000950170-24-032406
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240109
FILED AS OF DATE: 20240315
DATE AS OF CHANGE: 20240315
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Crowley John F
CENTRAL INDEX KEY: 0001400973
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33497
FILM NUMBER: 24756489
MAIL ADDRESS:
STREET 1: C/O AMICUS THERAPEUTICS, INC.
STREET 2: 1 CEDAR BROOK DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AMICUS THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001178879
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 200422823
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3675 MARKET STREET
CITY: PHILADELPHIA
STATE: PA
ZIP: 19104
BUSINESS PHONE: (215) 921-7600
MAIL ADDRESS:
STREET 1: 3675 MARKET STREET
CITY: PHILADELPHIA
STATE: PA
ZIP: 19104
FORMER COMPANY:
FORMER CONFORMED NAME: AMICUS THERAPEUTICS INC
DATE OF NAME CHANGE: 20020729
4/A
1
ownership.xml
4/A
X0508
4/A
2024-01-09
2024-01-11
true
0001178879
AMICUS THERAPEUTICS, INC.
FOLD
0001400973
Crowley John F
47 HULFISH STREET
PRINCETON
NJ
08542
true
true
false
false
Executive Chairman
true
Common Stock
2024-01-09
4
A
false
57620
0.0
A
995492
D
Common Stock
2024-01-09
4
F
false
36865
13.65
D
958627
D
Common Stock
2024-01-10
4
S
false
31614
13.6475
D
927013
D
Granted for the achievement of the 2021 PRSU TSR goal as determined by the Compensation and Leadership Development Committee of the Board of Directors.
On January 11, 2024, the reporting person filed a Form 4 which inadvertently excluded the acquisition of shares granted for the achievement of the TSR portion of the 2021 PRSU award and inadvertently reported incorrect holdings following both shares being withheld for taxes and a sale transaction. This Form 4 amendment reflects these transactions and the reporting person's holdings following these transactions correctly.
This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.48 to $13.96 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The sale transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2023.
/s/ Christian Formica, Attorney-in-Fact
2024-03-15